Last reviewed · How we verify
NCT03944200
A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State
Phase 1 trial testing DA-1229_01(A), Sugamet SR Tab 5/1000mg® in Type2 Diabetes in 30 participants. Completed in 25 March 2019.
25 March 2019
Quick facts
| Lead sponsor | Dong-A ST Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 30 |
| Start date | 7 February 2019 |
| Primary completion | 25 March 2019 |
| Estimated completion | 25 March 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- DA-1229_01(A), Sugamet SR Tab 5/1000mg® — full drug profile →
- Sugamet SR Tab 5/1000mg®, DA-1229_01(A) — full drug profile →
Conditions studied
- Type2 Diabetes — all drugs for Type2 Diabetes →
Sponsor
Dong-A ST Co., Ltd. — full company profile →
Who can join
19 and older, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study demonstrates the bioequivalence of DA-1229\_01(A) at Fed State when compared with Sugamet sustained-release(SR) Tab 5/1000mg® in healthy adults
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03944200
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Trials testing the same drug.
- NCT03939143 — A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State · Phase 1 · completed
Other recruiting trials for Type2 Diabetes
Currently open trials in the same condition.
- NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
- NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
- NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
- NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
- NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting
Other Dong-A ST Co., Ltd. trials
Trials by the same sponsor.
- NCT07342062 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State · Phase 1 · completed
- NCT07297940 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State · Phase 1 · completed
- NCT07027982 — A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjec · Phase 1 · completed
- NCT07046715 — Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 · Phase 1 · completed
- NCT07007533 — A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy A · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03944200 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dong-A ST Co., Ltd.
- Last refreshed: 20 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03944200.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing